Cargando…

Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio

OBJECTIVE: This study aimed to investigate the efficacy and tolerability of perampanel (PER) therapy and to optimize a specific plasma reference range for PER in children. Another major aim was to evaluate the potential determinators of PER concentration. METHODS: Concentrations obtained from 80 chi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yue, Dong, Na, Qin, Yu‐Xin, Dai, Hao‐Ran, Hu, Ya‐Hui, Zhao, Yue‐Tao, Guo, Hong‐Li, Zhang, Yuan‐Yuan, Chen, Jing, Lu, Xiao‐Peng, Chen, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712465/
https://www.ncbi.nlm.nih.gov/pubmed/36177517
http://dx.doi.org/10.1002/epi4.12653
_version_ 1784841794222030848
author Li, Yue
Dong, Na
Qin, Yu‐Xin
Dai, Hao‐Ran
Hu, Ya‐Hui
Zhao, Yue‐Tao
Guo, Hong‐Li
Zhang, Yuan‐Yuan
Chen, Jing
Lu, Xiao‐Peng
Chen, Feng
author_facet Li, Yue
Dong, Na
Qin, Yu‐Xin
Dai, Hao‐Ran
Hu, Ya‐Hui
Zhao, Yue‐Tao
Guo, Hong‐Li
Zhang, Yuan‐Yuan
Chen, Jing
Lu, Xiao‐Peng
Chen, Feng
author_sort Li, Yue
collection PubMed
description OBJECTIVE: This study aimed to investigate the efficacy and tolerability of perampanel (PER) therapy and to optimize a specific plasma reference range for PER in children. Another major aim was to evaluate the potential determinators of PER concentration. METHODS: Concentrations obtained from 80 children were analyzed for routine therapeutic drug monitoring (TDM) between 2021 and 2022. We retrospectively reviewed the clinical data of these patients and assessed the efficacy at 3 months after treatment initiation. Trough concentration‐to‐dose ratio (C (0)/Dose ratio) of PER was compared among patients on various potential influencing factors. RESULTS: A 3‐month PER therapy produced a ≥50% reduction in seizure frequency in 58.8% of patients. Twelve patients reported at least one adverse effect (AE), mainly dizziness. The monitoring data showed that the median C (0) was 325.5 ng/mL. Under maintenance dosages, approximately 75% of the C (0) values were 180.0‐610.0 ng/mL. The C (0)/Dose ratio in patients aged 1 to <4 was significantly lower by twofold than in those aged 4 to ≤12 years (P = 0.001). Enzyme‐inducing ASMs (EIASMs) decreased the C (0)/Dose ratio of PER by 25.9% (P = 0.165). In addition, seizure frequency reduction in responders was achieved at a median PER C (0) value of 357 ng/mL, which was similar to the value of 314 ng/mL found in nonresponders (P = 0.288). No significant difference was found in PER C (0) values between patients with and without AEs (P = 0.082). SIGNIFICANCE: In this study, PER treatment showed acceptable efficacy and tolerance in Chinese children with epilepsy. Contributing factors like age to variable C (0)/Dose ratios were identified, and complex PER‐ASMs interactions were observed. Notably, the reference range, that is, 180.0‐610.0 ng/mL, for routine PER monitoring may be more applicable for them. Routine TDM should be considered a positive attempt to manage the effectiveness and safety of PER.
format Online
Article
Text
id pubmed-9712465
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97124652022-12-02 Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio Li, Yue Dong, Na Qin, Yu‐Xin Dai, Hao‐Ran Hu, Ya‐Hui Zhao, Yue‐Tao Guo, Hong‐Li Zhang, Yuan‐Yuan Chen, Jing Lu, Xiao‐Peng Chen, Feng Epilepsia Open Original Articles OBJECTIVE: This study aimed to investigate the efficacy and tolerability of perampanel (PER) therapy and to optimize a specific plasma reference range for PER in children. Another major aim was to evaluate the potential determinators of PER concentration. METHODS: Concentrations obtained from 80 children were analyzed for routine therapeutic drug monitoring (TDM) between 2021 and 2022. We retrospectively reviewed the clinical data of these patients and assessed the efficacy at 3 months after treatment initiation. Trough concentration‐to‐dose ratio (C (0)/Dose ratio) of PER was compared among patients on various potential influencing factors. RESULTS: A 3‐month PER therapy produced a ≥50% reduction in seizure frequency in 58.8% of patients. Twelve patients reported at least one adverse effect (AE), mainly dizziness. The monitoring data showed that the median C (0) was 325.5 ng/mL. Under maintenance dosages, approximately 75% of the C (0) values were 180.0‐610.0 ng/mL. The C (0)/Dose ratio in patients aged 1 to <4 was significantly lower by twofold than in those aged 4 to ≤12 years (P = 0.001). Enzyme‐inducing ASMs (EIASMs) decreased the C (0)/Dose ratio of PER by 25.9% (P = 0.165). In addition, seizure frequency reduction in responders was achieved at a median PER C (0) value of 357 ng/mL, which was similar to the value of 314 ng/mL found in nonresponders (P = 0.288). No significant difference was found in PER C (0) values between patients with and without AEs (P = 0.082). SIGNIFICANCE: In this study, PER treatment showed acceptable efficacy and tolerance in Chinese children with epilepsy. Contributing factors like age to variable C (0)/Dose ratios were identified, and complex PER‐ASMs interactions were observed. Notably, the reference range, that is, 180.0‐610.0 ng/mL, for routine PER monitoring may be more applicable for them. Routine TDM should be considered a positive attempt to manage the effectiveness and safety of PER. John Wiley and Sons Inc. 2022-10-12 /pmc/articles/PMC9712465/ /pubmed/36177517 http://dx.doi.org/10.1002/epi4.12653 Text en © 2022 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Li, Yue
Dong, Na
Qin, Yu‐Xin
Dai, Hao‐Ran
Hu, Ya‐Hui
Zhao, Yue‐Tao
Guo, Hong‐Li
Zhang, Yuan‐Yuan
Chen, Jing
Lu, Xiao‐Peng
Chen, Feng
Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio
title Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio
title_full Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio
title_fullStr Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio
title_full_unstemmed Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio
title_short Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio
title_sort therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: focus on influencing factors on the plasma concentration‐to‐dose ratio
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712465/
https://www.ncbi.nlm.nih.gov/pubmed/36177517
http://dx.doi.org/10.1002/epi4.12653
work_keys_str_mv AT liyue therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio
AT dongna therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio
AT qinyuxin therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio
AT daihaoran therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio
AT huyahui therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio
AT zhaoyuetao therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio
AT guohongli therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio
AT zhangyuanyuan therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio
AT chenjing therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio
AT luxiaopeng therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio
AT chenfeng therapeuticdrugmonitoringofperampanelinchildrendiagnosedwithepilepsyfocusoninfluencingfactorsontheplasmaconcentrationtodoseratio